PR domain zinc finger protein 5 (UniProt Q9NQX1) is encoded by the PRDM1 gene (also known as BCS2, PFM2) in human (Gene ID 11107). PRDM proteins constitute a family of transcriptional regulators that are characterized by the presence of variable numbers of zinc finger domains and an N-terminal PR domain. PRDM5 can negatively regulate gene transcriptions by recruiting the G9a histone methyltransferase and histone deacetylases. PRDM5 can promote transcription by targeting enhancer-like elements or recruiting RNA polymerase II binding. PRDM5 is highly expressed in murine embryonic stem cells (mESCs) and associates with complexes involved in chromatin organization, such as Ctcf, Smc1 (cohesin), and TFIIIC, which indicates their involvement in chromatin organization. PRDM5 is often found silenced in human breast, ovarian, liver, and cervical cancers.
特異性
Expected to react with all four spliced isoforms
免疫原
GST-tagged recombinant protein corresponding to human PRDM5 near the N-terminus.
アプリケーション
Immunoprecipitation Analysis: A representative lot immunoprecipitated PRDM5 in mouse embryonic fibroblasts (Data courtesy of Dr. Anders H. Lund, University of Copenhagen, Denmark). Immunoprecipitation: A representative lot of this antibody immunoprecipitated PRDMS E9 and E10 intrahepatic cholangiocarcinoma (ICC) cells. (Seehawer, M., et al. (2018). Nature 562(7725); 69-75).
This Anti-PRDM5 Antibody is validated for use in Western Blotting and Immunoprecipitation for the detection of PRDM5 .
品質
Evaluated by Western Blotting in mouse ESC lysate.
Western Blotting Analysis: 8.0 µg/mL of this antibody detected PRDM5 in 10 µg of mouse ESC lysate.
The EMBO journal, 42(13), e112559-e112559 (2023-06-01)
Metastatic colonization of distant organs accounts for over 90% of deaths related to solid cancers, yet the molecular determinants of metastasis remain poorly understood. Here, we unveil a mechanism of colonization in the aggressive basal-like subtype of breast cancer that
Primary liver cancer represents a major health problem. It comprises hepatocellular carcinoma (HCC) and intrahepatic cholangiocarcinoma (ICC), which differ markedly with regards to their morphology, metastatic potential and responses to therapy. However, the regulatory molecules and tissue context that commit